RBC Capital cuts Dr Martens price target after profit warning
RBC Capital Markets cut its price target on on Monday to 65p from 85p as it reduced estimates following the bootmaker's FY25 guidance.
The bank said that despite the recent sell-off in the shares, it reckons it's too early to turn more positive on Dr Martens, given the stock remains in a "vicious" earnings downgrade cycle following its fifth profit warning.
"New CEO/CFO will likely undertake a detailed review of the business in the next 6-12 months, and above all else, drastic change is required, starting with financial discipline," it said.
"It is difficult to quantify a steady-state margin for DOCS at this stage and which may require right sizing its cost base."
The bank, which maintained its 'sector perform' rating on the shares, said it was reducing its FY25 EBIT estimate by 45%, its revenue forecast by 9% and its EPS forecast by 58%.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.